NTLA — Intellia Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.55bn
- $1.10bn
- $67.67m
Annual cashflow statement for Intellia Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -268 | -474 | -481 | -519 | -413 |
| Depreciation | |||||
| Non-Cash Items | 58.9 | 187 | 131 | 148 | 81.9 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -22.9 | -53.9 | -52.5 | 11.9 | -73.8 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -225 | -333 | -394 | -349 | -395 |
| Capital Expenditures | -12.8 | -13.6 | -14 | -5.78 | -1.13 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -538 | 174 | -17.4 | 131 | 229 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -551 | 160 | -31.3 | 126 | 228 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 737 | 583 | 130 | 186 | 131 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -39.1 | 410 | -295 | -37.6 | -35.2 |